Peculiar features and tailored management of adult cancers occurring in pediatric age

Expert Review of Anticancer Therapy

Volumn 10, Issue 11, 2010, Pages 1837-1851

  Ferrari, Andrea ^a   Casanova, Michela ^a   Massimino, Maura ^a   Sultan, Iyad ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

adult cancer; children; colorectal cancer; gastrointestinal stromal tumors; hepatocellular carcinoma; melanoma; nasopharyngeal carcinoma; rare pediatric tumors; thyroid cancer; TREP project

Indexed keywords

ADULT DISEASE; BREAST CANCER; CANCER DIAGNOSIS; CHILDHOOD DISEASE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SPECIALIST; MELANOMA; ONCOLOGY; RARE DISEASE; REVIEW; SURGEON; TREATMENT PLANNING;

ADULT; AGE FACTORS; CHILD; HUMANS; NEOPLASMS; PEDIATRICS;

EID: 78649302701     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.105     Document Type: Review

References (108)

1. Thun MJ, DeLancey JO, Center MM et al. The global burden of cancer: priorities for prevention. Carcinogenesis 31(1), 100-110 (2009).
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. IARC Press, Lyon, France (2004).
3. Conti EMS, Cercato MC, Gatta G et al. Childhood melanoma in Europe since 1978: a population-based survival study. Eur. J. Cancer 37, 780-784 (2001).
4. De Vries E, Steliarova-Foucher E, Spatz A et al. Skin cancer incidence and survival in European children and adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 42(13), 2170-2182 (2006).
5. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the Surveillance, Epidemiology and End Results database. J. Clin. Oncol. 23, 4753-4741 (2005).
6. Pastore G, De Salvo GL, Bisogno G et al. Evaluating the access to pediatric cancer care centres of children and adolescents with rare tumors in Italy: the TREP project. Ped. Blood Cancer 53(2), 152-155 (2009).
7. Milton GW, Shaw HM, Thompson JF, McCarthy WH. Cutaneous melanoma in childhood: incidence and prognosis. Australas. J. Dermatol. 38, 44-48 (1997).
8. Karlsson PM, Fredrikson M. Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken. Int. J. Cancer 121(2), 323-328 (2007).
9. Hayward NK. Genetics of melanoma predisposition. Oncogene 22, 3053-3062 (2003).
10. Whiteman DC, Milligan A, Welch J et al. Germline CDKN2A mutations in childhood melanoma. J. Natl Cancer Inst. 89, 1460(1997).
11. Danietti M, Ferrari A, Frigerio S et al. Cutaneous melanoma on childhood and adolescence shows frequent loss of INK4A and gain of KIT. J. Invest. Dermatol. 129(7), 1759-1768 (2009).
12. Uribe P, Wistuba II, Solar A et al. Comparative analysis of loss of heterozygosity and microsatellite instability in adult and pediatric melanoma. Am. J. Dermatopathol. 27, 279-285 (2005).
13. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum. Mol. Genet. 17 (R2), R109-R115 (2008).
14. Pappo AS. Melanoma in children and adolescents. Eur. J. Cancer 39, 2651-2661 (2003).
15. Lange JR, Palis BE, Chang DC et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J. Clin. Oncol. 25(11), 1363-1368 (2007).
16. Livestro DP, Kaine EM, Michaelson JS et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer 110(3), 614-624 (2007).
17. Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr. Melanoma in children. N. Engl. J. Med. 332, 656-662 (1995).
18. Mones JM, Ackerman AB. Melanomas in prepubescent children. Review comprehensively, critique historically, criteria diagnostically, and course biologically. Am. J. Dermatopathol. 25, 223-238 (2003).
19. Sander B, Karlsson P, Rosdahl I et al. Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: a clinico-pathological study of 130 cases. Int. J. Cancer 80, 646-651 (1999).
20. Ferrari A, Bono A, Baldi M et al. Does melanoma behave better in younger children than in adults? A retrospective study on 33 cases of childhood melanoma from a single institution. Pediatrics 115(3), 649-654 (2005).
21. Saenz NC, Saenz-Badillos J, Busam K et al. Childhood melanoma survival. Cancer 85, 750-754 (1999).
22. Spatz A, Ruiter D, Hardmeier T et al. Melanoma in childhood: an EORTC-MCG multicenter study on the clinicopathological aspects. Int. J. Cancer 4, 317-324 (1996).
23. Berk DR, LaBuz E, Dadras SS et al. Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults - the Stanford experience 1995-2008. Pediatr. Dermatol. 27(3), 244-254 (2010).
24. Cerroni L, Barnhill R, Elder D et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am. J. Surg. Pathol. 34(3), 314-326 (2010).
25. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol. Ther. 9(1), 40-49 (2006).
26. Richardson SK, Tannous ZS, Mihm MC. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J. Am. Acad. Dermatol. 47, 77-90 (2002).
27. Butter A, Hui T, Chapdelaine J et al. Melanoma in children and the use of sentinel lymph node biopsy J. Pediatr. Surg. 40(5), 797-800 (2005).
28. Roaten JB, Partrick DA, Bensard D et al Survival in sentinel lymph node-positive pediatric melanoma. J. Pediatr. Surg. 40(6), 988-992 (2005).
29. Chao MM, Schwartz JL, Wechsler DS et al. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr. Blood Cancer 44(5), 441-448 (2005).
30. Navid F, Furman WL, Fleming M et al. The feasibility of adjuvant interferon a-2b in children with high-risk melanoma. Cancer 103(4), 780-787 (2005). • Discusses the use of interferon in children with melanoma.
31. Shah NC, Gerstle JT, Stuart M et al Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J. Pediatr. Hematol. Oncol. 28(8), 496-500 (2006).
32. Rao BN, Pratt CB, Fleming ID et al Colon carcinoma in children and adolescents. A review of 30 cases. Cancer 55(6), 1322-1326 (1985).
33. LaQuaglia MP, Heller G, Filippa DA et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J. Pediatr. Surg 27(8), 1085-1089 (1992).
34. Pratt CB, Rao BN, Merchant TE et al. Treatment of colorectal carcinoma in adolescents and young adults with surgery, 5-fluorouracil/leucovorin/ interferon-a 2a and radiation therapy. Med. Pediatr. Oncol 32(6), 459-460 (1999).
35. Radhakrishnan CN, Bruce J. Colorectal cancers in children without any predisposing factors. A report of eight cases and review of the literature. Eur. J. Pediatr. Surg 13(1), 66-68 (2003).
36. Durno C, Aronson M, Bapat B et al Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut 54(8), 1146-1150 (2005).
37. Chantada GL, Perelli VB, Lombardi MG et al. Colorectal carcinoma in children, adolescents, and young adults. J. Pediatr. Hematol. Oncol. 27(1), 39-41 (2005).
38. Kravarusic D, Feigin E, Dlugy E et al. Colorectal carcinoma in childhood: a retrospective multicenter study. J. Pediatr. Gastroenterol. Nutr. 44(2), 209-211 (2007).
39. Ferrari A, Rognone A, Casanova M et al Colorectal carcinoma in children and adolescents: the experience of the Istituto Nazionale Tumori of Milan, Italy. Pediatr. Blood Cancer 50(3), 588-593 (2008).
40. Hill DA, Furman WL, Billups CA et al Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J. Clin. Oncol. 25(36), 5808-5814 (2007). • Largest series on childhood colorectal carcinoma.
41. Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Pediatr. Drugs 10(3), 177-192 (2008).
42. Sultan I, Rodriguez-Galindo C, El-Tani H et al. Colorectal cancer in children and adolescents: a population based study of 159 cases with comparison to adult cases. Cancer 116(3), 758-765 (2010).
43. Kim HC, Kim CN, Yu CS et al. Methylation of the hMLH1 and hMSH2 promoter in early-onset sporadic colorectal carcinomas with microsatellite instability Int. J. Colorectal Dis. 18(3), 196-202 (2003).
44. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 278(5340), 1043-1050 (1997).
45. Losi L, Di Gregorio C, Pedroni M et al. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am. J. Gastroenterol. 100(10), 2280-2287 (2005).
46. Simons AJ, Ker R, Groshen S et al. Variations in treatment of rectal cancer: the influence of hospital type and caseload. Dis. Colon Rectum 40, 641-646 (1997).
47. Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeon-related factors and outcome in rectal cancer. Ann. Surg 227, 157-167 (1998).
48. Chang MH. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int. 23, 309-314 (2003).
49. Czauderna P. Adult type vs. childhood hepatocellular carcinoma - are they the same or different lesions? Biology, natural history, prognosis and treatment. Med. Pediatr. Oncol. 39, 519-523 (2002).
50. Prokurat A, Kluge P, Kosciesza A et al. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing b-catenin. Med. Pediatr. Oncol 39, 510-518 (2000).
51. Mazzaferro V, Regallia E, Doci R et al Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N. Engl. J. Med. 334, 693-699 (1996).
52. Haberal M, Emiroglu R, Karakayali H et al. Expanded criteria for hepatocellular carcinoma and liver transplantation. Int. Surg 92, 110-115 (2007).
53. Tagge EP, Tagge DU, Reyes J et al Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J. Pediatr. Surg 27, 292-297 (1992).
54. Iwatsuki S, Starzl TE, Sheahan DG et al Hepatic resection vs. transplantation for hepatocellular carcinoma. Ann. Surg 214, 221-229 (1991).
55. Reyes JD, Carr B, Dvorchik I et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J. Pediatr. 136, 795-804 (2000).
56. Malogolowkin MH, Katzenstein H, Krailo MD et al. Feasibility and toxicity of chemoembolization for children with liver tumors. J. Clin. Oncol. 18, 1279-1284 (2000).
57. Llovet JM, Ricci S, Mazzaferro V et al Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
58. Katzenstein HM, Krailo MD, Malogolowkin MH et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group Intergroup Study. J. Clin. Oncol. 20, 2789-2797 (2002).
59. Czauderna P, Mackinlay G, Perilongo G et al. Hepatocellular carcinoma in children - results of the first prospective trial of the International Society of Pediatric Oncology (SIOP) - SIOPEL 1. J. Clin. Oncol. 20, 2798-2804 (2002). • International cooperative study on hepatocellular carcinoma in children.
60. Perilongo G, Shafford E, Maibach R et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Pediatric Oncology - SIOPEL 2. Eur. J. Cancer 40, 411-421 (2004).
61. Collini P, Mattavelli F, Spinelli C, Massimino M. Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age. Expert Rev. Anticancer Ther. 7(1), 23-30 (2007).
62. LaQuaglia MP, Corbally MT, Heller G et al. Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery 104, 1149-1156 (1988).
63. Massimino M, Collini P, Fagundes Leite S et al. Conservative surgical approach for thyroid and lymph-node involvement in papillary thyroid carcinoma of childhood and adolescence. Pediatr. Blood Cancer 46, 307-313 (2006). • Rationale for a conservative approach in pediatric thyroid cancer.
64. Collini P, Massimino M, Fagundes Leite S, et al. Papillary thyroid carcinoma of childhood and adolescence: a 30-year experience at the Istituto Nazionale Tumori in Milan. Pediatr. Blood Cancer 46, 300-306 (2006).
65. Collini P, Mattavelli F, Pellegrinelli A et al. Papillary carcinoma of the thyroid gland of childhood and adolescence: morphologic subtypes, biologic behaviour and prognosis. A clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period. Am. J. Surg. Pathol. 30(11), 1420-1426 (2006).
66. Cady B. Presidential address: beyond risk groups - a new look at differentiated thyroid cancer. Surgery 124, 947-957 (1998).
67. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 12(8), 683-702 (2002).
68. Rachmiel M, Charron M, Gupta A et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J. Pediatr. Endocrinol. Metab. 19(12), 1377-1393 (2006).
69. Bray F, Haugen M, Moger TA et al Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer Epidemiol. Biomarkers Prev. 17(9), 2356-2365 (2008).
70. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 4(1), 13-21 (2003).
71. Pathmanathan R, Prasad U, Sadler R et al Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333(11), 693-698 (1995).
72. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 15(10), 1765-1777 (2006).
73. Sultan I, Casanova M, Ferrari A et al Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr. Blood Cancer 55(2), 279-284 (2010). • Comparison between pediatric and adult nasopharyngeal carcinoma.
74. Langendijk JA, Leemans CR, Buter J et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J. Clin. Oncol. 22(22), 4604-4612 (2004).
75. Pao WJ, Hustu HO, Douglass EC et al Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int. J. Radiat. Oncol. Biol. Phys. 17(2), 299-305 (1989).
76. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 365(9476), 2041-2054 (2005).
77. Chan SH, Ng WT, Kam KL et al Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int. J. Radiat. Oncol Biol. Phys. 73(5), 1335-1342 (2009).
78. Chen MC, Feng IJ, Lu CH et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979-2003). Ann. Oncol. 19(6), 1180-1186 (2008).
79. Ulger S, Ulger Z, Yildiz F, Ozyar E. Incidence of hypothyroidism after radiotherapy for nasopharyngeal carcinoma. Med. Oncol. 24(1), 91-94 (2007).
80. Rodriguez-Galindo C, Wofford M, Castleberry RP et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer 103(4), 850-857 (2005).
81. Mertens R, Granzen B, Lassay L et al Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). Cancer 104(5), 1083-1089 (2005).
82. Comoli P, De Palma R, Siena S et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann. Oncol. 15(1), 113-117 (2004).
83. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105(5), 1898-1904 (2005).
84. Laskar S, Bahl G, Muckaden M et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensitymodulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 72(3), 728-736 (2008).
85. Varan A, Ozyar E, Corapçioglu F et al. Pediatric and young adult nasopharyngeal carcinoma patients treated with preradiation cisplatin and docetaxel chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1116-1120 (2009).
86. Ng SH, Chan SC, Yen TC et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur. J. Nucl. Med. Mol. Imaging 36(1), 12-22 (2009).
87. Ji MF, Wang DK, Yu YL et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br. J. Cancer 96(4), 623-630 (2007).
88. Guzzo M, Ferrari A, Marcon I et al. Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan. Pediatr. Blood Cancer 47(6), 806-810 (2006).
89. Shikhani AH, Johns ME. Tumors of the major salivary glands in children. Head Neck Surg. 10(4), 257-263 (1988).
90. Sultan I, Rodriguez-Galindo C, Al-Sharabati S, Guzzo M, Casanova M, Ferrari A. Salivary gland carcinomas in children and adolescents: a populationbased study, with comparison to adult cases. Head Neck (2010) (In press).
91. Okcu MF, Hicks J, Merchant TE et al. Nonrhabdomyosarcomatous soft tissue sarcomas. In: Principles and Practice of Pediatric Oncology (5th Edition). Pizzo PA, Poplack DC (Eds). Lippincott Williams & Wilkins, PA, USA, 1033-1073 (2006).
92. Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev. Anticancer Ther. 5(2), 307-318 (2005).
93. Ferrari A, Casanova M, Meazza C et al Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J. Clin. Oncol. 23, 4021-4030 (2005). • Defines 'adult-type' pediatric soft tissue sarcomas, and the largest published series on pediatric nonrhabdomyosarcoma soft-tissue sarcomas.
94. Ferrari A, Miceli R, Casanova M et al Adult-type soft tissue sarcomas in paediatric age: a nomogram-based prognostic comparison with adult sarcoma. Eur. J. Cancer 43(18), 2691-2697 (2007).
95. Ferrari A. Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma. Expert Rev. Anticancer Ther. 9(11), 1541-1543 (2009).
96. Sultan I, Rodriguez-Galindo C, Saab R et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology and End Results Program, 1983 to 2005: an analysis of 1268 patients. Cancer 115(15), 3537-3547 (2009).
97. Ferrari A, Gronchi A, Casanova M et al Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101, 627-634 (2004).
98. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumors (GIST) - update of the NCCN clinical practice guidelines. J. Natl Compr. Cancer Netw. 5(2), S1-S29 (2007).
99. Benesch M, Wardelmann E, Ferrari A et al. Gastrointestinal stromal tumors (GIST) in children and adolescents: a comprehensive review of the current literature. Ped. Blood Cancer 53, 1171-1179 (2009).
100. Janeway KA, Liegl B, Harlow B et al Pediatric KIT-wild-type and plateletderived growth factor receptor a-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 67, 9084-9088 (2007). • Insight into the peculiar biology of pediatric gastrointestinal stromal tumors.
101. Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol. Clin. North Am. 23(1), 15-34, (2009).
102. Kim SY, Janeway K, Pappo A. Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. Curr. Opin. Oncol. 22(4), 347-350 (2010).
103. Janeway KA, Zhu MJ, Barretina J et al Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF 1R genomic amplification. Int. J. Cancer DOI: 10.1002/ijc.25247 (2010) (Epub ahead of print).
104. Janeway KA, Albritton KH, Van Den Abbeele AD et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr. Blood Cancer 52(7), 767-771 (2009).
105. Ferrari A, Bisogno G, De Salvo GL et al The challenge of very rare tumours in childhood: the Italian TREP project. Eur. J. Cancer 43, 654-659 (2007). • Rationale and practical schemes for developing cooperative research on rare pediatric tumors.
106. Michalkiewicz E, Sandrini R, Figueiredo B et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Paediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 22(5), 838-845 (2004).
107. Priest JR, Messinger Y, Finkelstein MJ et al. Treatment modality vs outcome in Type I pleuropulmonary blastoma (PPB) - results from The PPB Registry Pediatr. Blood Cancer 44(6), 544(2005) (Abstract).
108. Ferrari A. The Challenge of Very Rare Pediatric Tumors: the Italian TREP Project. Educational Book, American Society of Clinical Oncology Annual Meeting, 620-624 (2009).